Most Read News

Mankind Pharma's stock increased by more than 4% after the block deal. Mankind Pharma's shares were trading at ₹2,169 on the NSE at 09.23 am.

The pressure from these major stocks pulled the benchmarks further down, reflecting investor concerns and market volatility.

The license, which is still being reviewed by the finance ministry, will remove the biggest impediment to the entity.

iDATA's audited consolidated financials show revenues of ~ ₹246 Crore and EBITDA of ~ ₹144 Crore in CY2023.

India's vehicle retail sales increased by only 0.73% year on year in June, owing to delayed monsoons in several parts of the nation.

CPPIB owned a 5.96% interest in Delhivery. On April 25, it reduced its shareholding in Delhivery by 2.77% through block trades.

As part of this collaboration, Infosys will migrate Sector Alarm's disparate on-premises ERP platform to Microsoft Dynamics 365 Finance and Operations (F&O), enhancing their financial and operational models.

The extension of infrastructure will make EV fast-charging more comfortable and accessible, allowing EV users to plan hassle-free long-distance trips.

The NSE indicated that the derivative contracts for these securities had surpassed 95% of the MWPL, leading to their inclusion in the ban period.

The company's revenue from operations decreased by 30.3% to ₹180.7 Crore, down from ₹259.3 Crore in the previous fiscal year.